Jazz Pharmaceuticals (JAZZ)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$227.32-3.13%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · JAZZ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is still in the top half of its industry but slipped notably this past month — worth watching.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 19.2% |
| Our one-year growth estimate | diamond | 5.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 13.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
JAZZ — President transition
Dated 2026-10-09
Chief Commercial Officer — Samantha Pearce: The filing announces a planned retirement of a senior executive with a defined timeline for succession, indicating an orderly transition rather than a sudden loss.
Why it matters: The sector has been a tailwind, but its growth trend is slowing. A rise in sector revenue growth would support that backdrop.
Supportive ifThe sector's three-year revenue growth rises above its current level near 9%.
Worry ifThe sector's three-year revenue growth falls below its current level near 9%.
Why it matters: Revenue growth is a stated company priority. Another increase would show that recent growth continued.
Watch forThe next reported quarter shows revenue growth above 10% year over year.
Also watch forThe next reported quarter shows revenue growth at or below 0% year over year.
Why it matters: KYRON is meant to support a U.S. drug filing. Seizure results will test the early trial signal.
Watch forJazz reports that KYRON met its main study goals and shows seizure drops in treated children.
Also watch forJazz reports that KYRON missed its main study goals, found no seizure drop, or faced a major delay.
Why it matters: Jazz said the charge will affect Q3 results. The report can show how much it changes reported profit.
Watch forThe Q3 report lists a pre-tax Actio charge near $755 million and gives clear results both with and without the charge.
Also watch forThe Q3 report shows a charge far above $755 million or gives no clear account of its effect on results.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$114 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $286 loss on $10,000 · 2.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,162 loss on $10,000 · 21.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The notes add debt, and some may be exchanged for Jazz shares. Final terms and share use show the cost.
Worry ifA filing shows Jazz issuing more than 5,014,125 shares when notes are exchanged. It may also report extra costs beyond the stated 1.875% interest.
Less concerning ifJazz reports no note exchange into shares and no added note cost beyond the stated 1.875% interest.